{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male%2C+Healthy+Normal+Subjects",
    "query": {
      "condition": "Male, Healthy Normal Subjects"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 50,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male%2C+Healthy+Normal+Subjects&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T22:44:10.058Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06397872",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "100 mg Resmetirom Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 28,
      "start_date": "2024-03-06",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Tampa, Florida • Chicago, Illinois",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06397872"
    },
    {
      "nct_id": "NCT00834275",
      "title": "Cefadroxil 500 mg Capsules Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Cefadroxil 500 mg Capsules",
          "type": "DRUG"
        },
        {
          "name": "DURICEF® capsules 500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2004-09",
      "completion_date": "2004-10",
      "has_results": true,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834275"
    },
    {
      "nct_id": "NCT03506854",
      "title": "Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "ISIS 681257",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akcea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-03-20",
      "completion_date": "2018-10-11",
      "has_results": false,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03506854"
    },
    {
      "nct_id": "NCT02772159",
      "title": "TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "TD-4208",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "19 Years to 55 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2015-06",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02772159"
    },
    {
      "nct_id": "NCT01309438",
      "title": "A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (normal renal function)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban (mild and moderate renal impairment)",
          "type": "DRUG"
        },
        {
          "name": "Erythromycin (normal renal function)",
          "type": "DRUG"
        },
        {
          "name": "Erythromycin (mild and moderate renal function)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2011-02",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-10-08",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01309438"
    },
    {
      "nct_id": "NCT01367496",
      "title": "Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "SC Methylnaltrexone (MNTX)",
          "type": "DRUG"
        },
        {
          "name": "IV Methylnaltrexone (MNTX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2002-06",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01367496"
    },
    {
      "nct_id": "NCT00855088",
      "title": "Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV/AIDS",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Etravirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "MALE",
        "summary": "18 Years to 49 Years · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2009-07",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2011-05-13",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855088"
    },
    {
      "nct_id": "NCT02431481",
      "title": "Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Renal Function",
        "Impaired Renal Function"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-10-23",
      "completion_date": "2018-05-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431481"
    },
    {
      "nct_id": "NCT02211469",
      "title": "A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "BMS-986104",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "MALE",
        "summary": "18 Years to 49 Years · Male only"
      },
      "enrollment_count": 41,
      "start_date": "2014-08",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-09-18",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02211469"
    },
    {
      "nct_id": "NCT01675973",
      "title": "A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Renal Impairment"
      ],
      "interventions": [
        {
          "name": "RANEXA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2012-07",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-12-06",
      "last_synced_at": "2026-09-13T22:44:10.058Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01675973"
    }
  ]
}